title: Sustained release and enhanced bioavailability of injectable scutellarin-loaded bovine serum albumin nanoparticles.
abstract: The aim of this study is to characterize the in-vitro physicochemical and in-vivo pharmacokinetic properties of the scutellarin-loaded bovine serum albumin nanoparticles (STA-BSA-NPs). STA existed as amorphous form in the nanoparticles. Reconstituted STA-BSA-NPs had an average particle size of 283.4 nm and a zeta potential of +17.95 mV. The in-vitro sustained release profile was well fitted with Weibull distribution model. In comparison to STA solution, STA-BSA-NPs exhibited a significantly higher plasma concentration from 20 min to 6 h after intravenous administration to rats. In addition, significantly higher AUC(0-inf) (2.8-fold), prolonged elimination half-life (4.2-fold) and lower clearance (2.7-fold) were achieved.
authors.affiliation: School of Traditional Chinese Medicine, China Pharmaceutical University, Nanjing 210009, PR China.
authors.forename: Yuanfeng
authors.initials: Y
authors.lastname: Wei
authors.affiliation: School of Traditional Chinese Medicine, China Pharmaceutical University, Nanjing 210009, PR China.
authors.forename: Laicun
authors.initials: L
authors.lastname: Li
authors.affiliation: School of Traditional Chinese Medicine, China Pharmaceutical University, Nanjing 210009, PR China.
authors.forename: Yifeng
authors.initials: Y
authors.lastname: Xi
authors.affiliation: School of Traditional Chinese Medicine, China Pharmaceutical University, Nanjing 210009, PR China.
authors.forename: Shuai
authors.initials: S
authors.lastname: Qian
authors.affiliation: School of Traditional Chinese Medicine, China Pharmaceutical University, Nanjing 210009, PR China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Gao
authors.affiliation: Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, PR China. Electronic address: amicute@163.com.
authors.forename: Jianjun
authors.initials: J
authors.lastname: Zhang
mesh_terms: D061605:Administration, Intravenous; D000818:Animals; D047310:Apigenin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D019540:Area Under Curve; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004337:Drug Carriers / Q000737:chemistry; D065546:Drug Liberation; D005965:Glucuronates / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006207:Half-Life; D008297:Male; D053758:Nanoparticles; D010316:Particle Size; D051381:Rats; D017207:Rats, Sprague-Dawley; D012710:Serum Albumin, Bovine / Q000737:chemistry*
chemical_list: D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005965:Glucuronates; C484876:scutellarin; D012710:Serum Albumin, Bovine; D047310:Apigenin
keywords: Albumin nanoparticles; Bioavailability; Elimination half-life; Scutellarin; Sustained release